Skip to main content
. 2013 Feb;98(2):e20–e22. doi: 10.3324/haematol.2012.082404

Figure 1.

Figure 1.

Monitoring of CD19/CD103 positive cells in peripheral blood after three months of treatment with vemurafenib. Determination of CD19+CD103+ cell number in time course of vemurafenib treatment (from Day 0 to Day 56) and one month after the end of treatment (Day 90).